[HTML][HTML] The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson's Disease
A Mori, JF Chen, S Uchida, C Durlach, SM King… - Molecules, 2022 - mdpi.com
The adenosine A2A receptor subtype is recognized as a non-dopaminergic
pharmacological target for the treatment of neurodegenerative disorders, notably …
pharmacological target for the treatment of neurodegenerative disorders, notably …
Adenosine receptor control of cognition in normal and disease
JF Chen - International review of neurobiology, 2014 - Elsevier
Adenosine and adenosine receptors (ARs) are increasingly recognized as important
therapeutic targets for controlling cognition under normal and disease conditions for its dual …
therapeutic targets for controlling cognition under normal and disease conditions for its dual …
Caffeine protects against oxidative stress and Alzheimer's disease-like pathology in rabbit hippocampus induced by cholesterol-enriched diet
JRP Prasanthi, B Dasari, G Marwarha, T Larson… - Free Radical Biology …, 2010 - Elsevier
Cholesterol has been linked to the pathogenesis of sporadic Alzheimer's disease (AD) as a
risk factor increasing β-amyloid (Aβ) and oxidative stress levels. Caffeine has antioxidant …
risk factor increasing β-amyloid (Aβ) and oxidative stress levels. Caffeine has antioxidant …
[HTML][HTML] Dopamine D2 and adenosine A2A receptors regulate NMDA-mediated excitation in accumbens neurons through A2A–D2 receptor heteromerization
Bursting activity of striatal medium spiny neurons results from membrane potential
oscillations between a down-and an upstate that could be regulated by G-protein-coupled …
oscillations between a down-and an upstate that could be regulated by G-protein-coupled …
Caffeine and the dopaminergic system
O Cauli, M Morelli - Behavioural pharmacology, 2005 - journals.lww.com
Caffeine is the most widely consumed psychostimulant substance, being self-administered
throughout a wide range of conditions and present in numerous dietary products. Due to its …
throughout a wide range of conditions and present in numerous dietary products. Due to its …
Emerging therapies for Parkinson's disease: from bench to bedside
The prevalence of Parkinson's disease (PD) increases with age and is projected to increase
in parallel to the rising average age of the population. The disease can have significant …
in parallel to the rising average age of the population. The disease can have significant …
Adenosine receptor neurobiology: overview
Adenosine is a naturally occurring nucleoside that is distributed ubiquitously throughout the
body as a metabolic intermediary. In the brain, adenosine functions as an important …
body as a metabolic intermediary. In the brain, adenosine functions as an important …
Adenosine–cannabinoid receptor interactions. Implications for striatal function
S Ferré, C Lluís, Z Justinova, C Quiroz… - British journal of …, 2010 - Wiley Online Library
Adenosine and endocannabinoids are very ubiquitous non‐classical neurotransmitters that
exert a modulatory role on the transmission of other more 'classical'neurotransmitters. In this …
exert a modulatory role on the transmission of other more 'classical'neurotransmitters. In this …
Adenosine A2A receptor as potential therapeutic target in neuropsychiatric disorders
MR Domenici, A Ferrante, A Martire, V Chiodi… - Pharmacological …, 2019 - Elsevier
Abstract Adenosine A 2A receptor (A 2A R) is a G-protein coupled receptor that regulates
several important functions in the central nervous system. Large amount of preclinical data …
several important functions in the central nervous system. Large amount of preclinical data …
Role of the central ascending neurotransmitter systems in the psychostimulant effects of caffeine
S Ferré - Journal of Alzheimer's Disease, 2010 - content.iospress.com
Caffeine is the most consumed psychoactive drug in the world. It is a non-selective
adenosine receptor antagonist that in the brain targets mainly adenosine A 1 and A 2A …
adenosine receptor antagonist that in the brain targets mainly adenosine A 1 and A 2A …